Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
Seqirus S.r.l., Monteriggioni, Italy.
Hum Vaccin Immunother. 2023 Aug;19(2):2257048. doi: 10.1080/21645515.2023.2257048. Epub 2023 Oct 1.
Influenza is a vaccine-preventable disease and a global public health problem. Although most national influenza vaccination recommendations focus on subjects aged ≥65 years, an extensive burden of influenza has also been reported in those aged ≥50 years and is exacerbated by immune system aging. The main purpose of this review is to provide an overview of the burden of influenza and its potential prevention within the 50-64 age-group. These subjects account for a large proportion of the workforce, and play a central economic and social role. Individuals aged 50-64 years had a 3-times higher rate of hospitalization and a 9-fold higher mortality rate attributable to influenza than those aged 18-49-years, generating higher influenza-related hospitalization costs. Available data suggest that including healthy subjects aged 50-64 years in influenza vaccination recommendations would allow a broader population to be reached, reducing the economic and social burden of influenza.
流感是一种可通过疫苗预防的疾病,也是一个全球性的公共卫生问题。虽然大多数国家的流感疫苗接种建议主要针对年龄≥65 岁的人群,但年龄≥50 岁的人群也报告了广泛的流感负担,并且免疫系统老化会使这种负担加重。本次综述的主要目的是概述 50-64 岁年龄组的流感负担及其潜在的预防措施。这些人群占劳动力的很大比例,在经济和社会中发挥着核心作用。与 18-49 岁年龄组相比,50-64 岁年龄组的住院率高 3 倍,流感相关死亡率高 9 倍,导致流感相关住院费用增加。现有数据表明,将健康的 50-64 岁人群纳入流感疫苗接种建议中,可以覆盖更广泛的人群,从而减轻流感带来的经济和社会负担。